SG11202106637SA - Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer - Google Patents
Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancerInfo
- Publication number
- SG11202106637SA SG11202106637SA SG11202106637SA SG11202106637SA SG11202106637SA SG 11202106637S A SG11202106637S A SG 11202106637SA SG 11202106637S A SG11202106637S A SG 11202106637SA SG 11202106637S A SG11202106637S A SG 11202106637SA SG 11202106637S A SG11202106637S A SG 11202106637SA
- Authority
- SG
- Singapore
- Prior art keywords
- mat2a
- aza
- methods
- treating cancer
- heterobicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785519P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068652 WO2020139991A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106637SA true SG11202106637SA (en) | 2021-07-29 |
Family
ID=69400625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106637SA SG11202106637SA (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20220144820A1 (en) |
| EP (1) | EP3902803B1 (en) |
| JP (2) | JP7418441B2 (en) |
| KR (1) | KR20220051301A (en) |
| AR (1) | AR117544A1 (en) |
| AU (1) | AU2019416349B2 (en) |
| BR (1) | BR112021012595A2 (en) |
| CA (1) | CA3124952A1 (en) |
| CL (1) | CL2021001721A1 (en) |
| CO (1) | CO2021009879A2 (en) |
| CR (1) | CR20210410A (en) |
| DK (1) | DK3902803T3 (en) |
| EA (1) | EA202191801A1 (en) |
| ES (1) | ES2942310T3 (en) |
| FI (1) | FI3902803T3 (en) |
| GE (1) | GEP20237519B (en) |
| HR (1) | HRP20230161T1 (en) |
| HU (1) | HUE061834T2 (en) |
| IL (1) | IL284326B1 (en) |
| JO (1) | JOP20210172A1 (en) |
| LT (1) | LT3902803T (en) |
| MA (1) | MA54608B1 (en) |
| MD (1) | MD3902803T2 (en) |
| MX (1) | MX2021007829A (en) |
| PE (1) | PE20212090A1 (en) |
| PL (1) | PL3902803T3 (en) |
| PT (1) | PT3902803T (en) |
| RS (1) | RS64135B1 (en) |
| SG (1) | SG11202106637SA (en) |
| SI (1) | SI3902803T1 (en) |
| TW (1) | TWI816962B (en) |
| UA (1) | UA127525C2 (en) |
| WO (1) | WO2020139991A1 (en) |
| ZA (1) | ZA202104423B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3894396A1 (en) | 2018-12-10 | 2021-10-20 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| EP4188920A1 (en) * | 2020-07-31 | 2023-06-07 | Tango Therapeutics, Inc. | Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers |
| CN115960098A (en) * | 2020-09-11 | 2023-04-14 | 上海凌达生物医药有限公司 | Preparation method and application of nitrogen-containing fused ring compounds |
| CN115141202A (en) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | Pyrimidopyrazinone compounds and uses thereof |
| CN117412967A (en) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | Methionine adenosine transferase 2A inhibitors |
| US20230192679A1 (en) * | 2021-12-17 | 2023-06-22 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP3507290A1 (en) * | 2016-08-31 | 2019-07-10 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| EP3630724B1 (en) | 2017-05-22 | 2021-04-28 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| UA127059C2 (en) | 2018-03-30 | 2023-03-29 | Ле Лаборатуар Сервьє | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
-
2019
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/en unknown
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/en unknown
- 2019-12-27 EA EA202191801A patent/EA202191801A1/en unknown
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/en active
- 2019-12-27 ES ES19845796T patent/ES2942310T3/en active Active
- 2019-12-27 SI SI201930515T patent/SI3902803T1/en unknown
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/en active
- 2019-12-27 AR ARP190103903A patent/AR117544A1/en unknown
- 2019-12-27 RS RS20230240A patent/RS64135B1/en unknown
- 2019-12-27 IL IL284326A patent/IL284326B1/en unknown
- 2019-12-27 CR CR20210410A patent/CR20210410A/en unknown
- 2019-12-27 CA CA3124952A patent/CA3124952A1/en active Pending
- 2019-12-27 BR BR112021012595-7A patent/BR112021012595A2/en unknown
- 2019-12-27 JO JOP/2021/0172A patent/JOP20210172A1/en unknown
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/en active Application Filing
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/en unknown
- 2019-12-27 UA UAA202104321A patent/UA127525C2/en unknown
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/en active Active
- 2019-12-27 MA MA54608A patent/MA54608B1/en unknown
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/en unknown
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/en unknown
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/en unknown
- 2019-12-27 TW TW108148216A patent/TWI816962B/en active
- 2019-12-27 KR KR1020217023828A patent/KR20220051301A/en unknown
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/en active Active
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/en unknown
- 2019-12-27 US US17/418,442 patent/US20220144820A1/en active Pending
- 2019-12-27 PT PT198457962T patent/PT3902803T/en unknown
-
2021
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/en unknown
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/en unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277665A (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| IL284324A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| IL288395A (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| IL272948B1 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| IL272877A (en) | Shp2 inhibitor compositions and methods for treating cancer | |
| IL284326A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| EP3464643A4 (en) | Use of ezh2 inhibitors for treating cancer | |
| IL254842B (en) | Therapeutic compositions and methods of use for treating cancer | |
| HK1244436A1 (en) | Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer | |
| IL274198A (en) | Use of nox inhibitors for treatment of cancer | |
| EP3576766A4 (en) | Cyclin g1 inhibitors and related methods of treating cancer | |
| IL277918A (en) | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer | |
| EP3630080A4 (en) | Use of ezh2 inhibitors for treating cancer | |
| EP3966208A4 (en) | Compounds and methods for treating cancer | |
| IL291424A (en) | Use of dkk-1 inhibitors for treating cancer | |
| IL276203A (en) | Compositions and methods of treating cancer | |
| EP3843726A4 (en) | Parp inhibitors for treating cancer and asthma | |
| FI3630112T3 (en) | Combination of regorafenib and nivolumab for treating cancer | |
| GB201709417D0 (en) | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer | |
| IL288003A (en) | Methods of treating cancer using chk1 inhibitors | |
| GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer | |
| EP3615052A4 (en) | Use of hcn inhibitors for treatment of cancer | |
| IL287538A (en) | Compositions and methods for treatment of cancer | |
| IL263184A (en) | Method of treating cancer and compositions for same |